The makers of mifepristone, a key drug in the abortion pill regimen, have asked the Supreme Court to allow the medication to be sent by mail after a lower court blocked the practice. The emergency application was filed on May 2, one day after the U.S. Court of Appeals for the Fifth Circuit paused a Food and Drug Administration (FDA) rule permitting mail-order distribution of the drug.
Immediate Action & Core Facts
The Supreme Court application follows a ruling by the Fifth Circuit that temporarily blocked FDA guidelines from 2023, which had eased access to mifepristone. The lower court's order took effect immediately, citing an ongoing safety review initiated during the Trump administration. Danco Laboratories, the manufacturer of mifepristone, argued in its filing that the ruling 'causes immediate confusion and dramatic upheaval' for patients, providers, and pharmacies nationwide.
Deeper Dive & Context
The application comes two years after the Supreme Court unanimously rejected a similar legal challenge to mifepristone, concluding that the plaintiffs lacked standing. In the current case, Louisiana is the primary challenger, arguing that the FDA's approval of the drug impacts the state. Danco Laboratories contends that Louisiana does not have standing to bring the case and that the ruling disrupts time-sensitive medical decisions.
The FDA's 2023 guidelines had expanded access to mifepristone, allowing it to be prescribed via telehealth and dispensed by mail. The Fifth Circuit's ruling has raised questions about the immediate availability of the drug in states where it remains legal. The Supreme Court's decision on the emergency application could have significant implications for abortion access and the regulatory authority of the FDA.